Buy Or Sell Opportunity • 3h
Now 21% undervalued Over the last 90 days, the stock has risen 17% to €21.60. The fair value is estimated to be €27.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 3.1% in a year. Earnings are forecast to grow by 36% in the next year. Recent Insider Transactions • May 27
Independent Director recently bought €141k worth of stock On the 18th of May, William Cornog bought around 10k shares on-market at roughly €14.07 per share. This transaction increased William's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €445k more in shares than they have sold in the last 12 months. Board Change • May 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Dipal Doshi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annonce • Apr 30
Azenta, Inc. to Report Q2, 2026 Results on May 06, 2026 Azenta, Inc. announced that they will report Q2, 2026 results Pre-Market on May 06, 2026 Annonce • Apr 08
Azenta, Inc. Announces Executive Changes Azenta, Inc. announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer. This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market adoption and performance. Ginger Zhou will step down from her role as President of the Multiomics business and will continue to support the Company in an advisory capacity through November 2026 to ensure continuity and a smooth transition as the business advances into its next phase of execution. Mr. Martin most recently served as Chief Executive Officer and a member of the Board of Directors of Maravai Life Sciences, where he led strategic and operational transformation across a multi-segment life sciences platform. Prior to Maravai, he served in senior leadership roles at Danaher Corporation, including Senior Vice President, Genomic Medicines, and President of Integrated DNA Technologies (IDT). Mr. Martin joined Danaher following their 2018 acquisition of IDT, after helping to lead the sale process. Prior to acquisition, Mr. Martin spent more than two decades at IDT in positions of increasing responsibility where he helped drive global expansion through organic and inorganic growth investments, sustaining double-digit growth for the entire period. Mr. Martin holds a bachelor's degree in biochemistry from the University of Iowa. Annonce • Feb 04
Azenta, Inc. Reiterates Earnings Guidance for Full Year Fiscal 2026 Azenta, Inc. reiterated earnings guidance for full year fiscal 2026. For the period, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025. Annonce • Feb 03
Azenta, Inc. Announces Resignation of Alan P. Malus from Board of Directors and Member of Human Resources and Compensation Committee, Effective January 29, 2026 Azenta, Inc. was notified that Alan P. Malus resigned from the Company's Board of Directors, effective January 29, 2026. Mr. Malus also served as a member of the Human Resources and Compensation Committee. His resignation was due to full time responsibilities with another company, which will prevent him from devoting sufficient time to his duties with the Company. Annonce • Jan 22
Azenta, Inc. to Report Q1, 2026 Results on Feb 04, 2026 Azenta, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 04, 2026 Annonce • Dec 19
Azenta, Inc., Annual General Meeting, Jan 28, 2026 Azenta, Inc., Annual General Meeting, Jan 28, 2026. Annonce • Dec 11
Azenta, Inc. (NasdaqGS:AZTA) announces an Equity Buyback for $250 million worth of its shares. Azenta, Inc. (NasdaqGS:AZTA) announces a share repurchase program. Under the program, the company will repurchase up to $250 million in common stock. The purpose of the program is to enhance shareholder value and capitalize on undervaluation. The program will be funded from Company’s available cash reserves, operating cash flow, or other sources as determined by management, consistent with the Company’s financial policies. The program will be valid till December 31, 2028. Annonce • Dec 03
Azenta, Inc. announced delayed annual 10-K filing On 12/02/2025, Azenta, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annonce • Nov 21
Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2026 Azenta, Inc. provided earnings guidance for the fiscal year 2026. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025. Annonce • Nov 13
Azenta, Inc. to Report Q4, 2025 Results on Nov 21, 2025 Azenta, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 21, 2025 Annonce • Aug 05
Azenta, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025 Azenta, Inc. reiterated earnings guidance for the fiscal year 2025. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024. Annonce • Jul 24
Azenta, Inc. to Report Q3, 2025 Results on Aug 05, 2025 Azenta, Inc. announced that they will report Q3, 2025 results Pre-Market on Aug 05, 2025 Annonce • Jul 03
Azenta, Inc Announces Resignation of Violetta Hughes as Chief Accounting Officer, Effective August 2025 On June 27, 2025, Azenta, Inc. received notice from Violetta Hughes, Vice President and Chief Accounting Officer (Principal Accounting Officer), of her voluntary resignation from this position and from all director and officer positions with the Company’s subsidiaries, effective August 6, 2025. Ms. Hughes is resigning to pursue opportunities outside of the Company. Ms. Hughes’ resignation is not the result of any disagreement with the Company or its Board of Directors on any matter relating to its operations, policies, or practices, including any matters concerning the Company’s controls or any financial or accounting-related matters or disclosures. Ms. Hughes will work through the Separation Date to ensure a smooth transition of her responsibilities. Annonce • May 07
Azenta, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025 Azenta, Inc. reiterated earnings guidance for the fiscal year 2025. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024. Annonce • Apr 25
Azenta, Inc. to Report Q2, 2025 Results on May 07, 2025 Azenta, Inc. announced that they will report Q2, 2025 results Pre-Market on May 07, 2025 Annonce • Apr 10
David Wang Cease to Be President of Sample Management Solutions of Azenta, Inc On April 7, 2025, Azenta, Inc. and David Wang, President of Sample Management Solutions, agreed that Mr. Wang's employment with the Company would cease effective April 9, 2025. Annonce • Jan 31
Azenta, Inc. Announces the Election of Dipal Doshi to Its Board of Directors Azenta, Inc. announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier January 30, 2025. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. About Dipal Doshi: Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior-level positions at a healthcare private equity fund and Catalent. Earlier in his career, Mr. Doshi worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company. Mr. Doshi holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. Dipal also serves on the Board of Directors at ashibio, a privately held, clinical-stage biotechnology company. He is also a Fellow of the Aspen Institute and serves on the Board of Advisors of Life Science Cares Boston. Annonce • Jan 28
Azenta, Inc. to Report Q1, 2025 Results on Feb 05, 2025 Azenta, Inc. announced that they will report Q1, 2025 results Pre-Market on Feb 05, 2025 Annonce • Dec 18
Azenta, Inc., Annual General Meeting, Jan 30, 2025 Azenta, Inc., Annual General Meeting, Jan 30, 2025. Annonce • Nov 25
Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector) Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector) Reported Earnings • Nov 14
Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023) Full year 2024 results: US$3.09 loss per share (further deteriorated from US$0.19 loss in FY 2023). Revenue: US$656.3m (down 1.3% from FY 2023). Net loss: US$164.2m (loss widened US$151.3m from FY 2023). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Annonce • Nov 02
Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test Azenta, Inc. announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. In contrast, Azenta's test makes use of PacBio's Revio sequencer to obtain long and highly accurate HiFi sequencing reads to cover regions that are inaccessible by short reads. Performed within GENEWIZ from Azenta Life Sciences CLIA certified and CAP accredited clinical genomics laboratory, the test enables precise detection of a range of complex genomic alterations that are features of many rare diseases and undetectable by traditional approaches. This allows for a view of the genome with unprecedented comprehensiveness. Breakeven Date Change • Aug 15
Forecast to breakeven in 2026 The 6 analysts covering Azenta expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$1.82m in 2026. Average annual earnings growth of 95% is required to achieve expected profit on schedule. New Risk • Aug 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$16m net loss in 2 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Breakeven Date Change • Aug 07
No longer forecast to breakeven The 5 analysts covering Azenta no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$3.22m in 2026. New consensus forecast suggests the company will make a loss of US$10.5m in 2026. Annonce • Jul 25
Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024 Azenta, Inc. announced that they will report Q3, 2024 results After-Market on Aug 06, 2024 Annonce • May 10
Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024 Azenta, Inc. provided earnings guidance for the full fiscal year 2024. The company expected revenue in the range of $659 million to $671 million, due to the timing of B Medical revenue. Reported Earnings • May 09
Second quarter 2024 earnings released: US$2.47 loss per share (vs US$0.029 loss in 2Q 2023) Second quarter 2024 results: US$2.47 loss per share (further deteriorated from US$0.029 loss in 2Q 2023). Revenue: US$159.1m (up 7.2% from 2Q 2023). Net loss: US$136.9m (loss widened US$134.9m from 2Q 2023). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • May 07
Now 22% overvalued Over the last 90 days, the stock has fallen 15% to €51.50. The fair value is estimated to be €42.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years. Annonce • May 03
Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024 Azenta, Inc. announced that they will report Q2, 2024 results After-Market on May 08, 2024 Buy Or Sell Opportunity • Apr 13
Now 21% overvalued Over the last 90 days, the stock has fallen 11% to €52.50. The fair value is estimated to be €43.54, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years. New Risk • Mar 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (US$27m net loss next year). New Risk • Feb 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$17m Forecast net loss in 2 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Board Change • Feb 06
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Martin Madaus was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annonce • Jan 26
Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024 Azenta, Inc. announced that they will report Q1, 2024 results After-Market on Feb 07, 2024 Annonce • Jan 19
Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Azenta, Inc. provided earnings guidance for the fiscal year 2024 . For the year, company expects revenue growth to be in range of 5% to 8%. Annonce • Jan 18
Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc On January 10, 2024, Ellen M. Zane notified Azenta, Inc. that she has decided not to stand for election to the Board of Directors of the Company at the 2024 Annual Meeting of the Company’s Stockholders to be held on January 30, 2024, and, as a result, Ms. Zane will no longer be a nominee for re-election at the 2024 Annual Meeting and her tenure as a director will end as of the 2024 Annual Meeting. No other nominee for election at the 2024 Annual Meeting will be named in place of Ms. Zane and the size of the Board will be reduced from ten to nine members effective as of the 2024 Annual Meeting. Ms. Zane’s decision not to stand for election was not due to any disagreement with the Company. Annonce • Dec 16
Azenta, Inc., Annual General Meeting, Jan 30, 2024 Azenta, Inc., Annual General Meeting, Jan 30, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect ten director nominees; to approve, by a non-binding advisory vote, the compensation of the Company’s named executive officers; to recommend the frequency of holding an advisory vote on executive compensation; to ratify PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for the 2024 fiscal year; and to consider any other business as may properly come before the meeting. Annonce • Nov 15
Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024 Azenta, Inc. provided earnings guidance for the Full Year Fiscal 2024. For the year, the company expects Total revenue is expected to be in the range of $696 to $718 million, reflecting total organic revenue growth in the range of 5% to 8% relative to Fiscal 2023. Reported Earnings • Nov 14
Full year 2023 earnings released: US$0.19 loss per share (vs US$0.15 loss in FY 2022) Full year 2023 results: US$0.19 loss per share (further deteriorated from US$0.15 loss in FY 2022). Revenue: US$665.1m (up 20% from FY 2022). Net loss: US$12.9m (loss widened 14% from FY 2022). Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Annonce • Nov 09
Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023 Azenta, Inc. announced that they will report Q4, 2023 results After-Market on Nov 13, 2023 Annonce • Nov 02
Politan Capital Provides Information to the Shareholders On November 1, 2023, Politan Capital Management LP announced that it has entered into a non-disclosure agreement with Azenta, Inc and is currently engaging in discussions with the Company’s management and board of directors concerning the Company’s business, strategies and corporate governance. Coincident with these discussions, due to the November 2, 2023 nomination deadline in the Amended and Restated Bylaws of the Company (the Bylaws), on October 30, 2023, Politan Capital NY LLC, in compliance with the Bylaws, submitted to the Company its formal notice to nominate candidates for election to the Board, one of whom is Politan’s Managing Partner and Chief Investment Officer Quentin Koffey. Annonce • Sep 28
Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023 Azenta, Inc. announced that Herman Cueto will join Azenta as Chief Financial Officer, effective October 16, 2023. Mr. Cueto, who comes from BD (Becton, Dickinson and Company), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Mr. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of CR Bard. Mr. Robertson is expected to remain the Company’s Principal Financial Officer until the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023, after which time, Mr. Cueto will become the Company’s Principal Financial Officer. Mr. Cueto, age 49, previously served as the Senior Vice President of Finance of Becton, Dickinson and Company (NYSE: BDX), since June 2021, and served in senior financial and operations roles at Becton, Dickinson and Company since December 2017 including as the Senior Vice President and Chief Financial Officer of Becton, Dickinson and Company’s Medical Segment from January 2021 to June 2021. Prior to that, Mr. Cueto was at C.R. Bard, Inc. for fourteen years, most recently as Vice President and Group CFO. Mr. Cueto earned a Bachelor of Science and Master’s degrees from Fairleigh Dickinson University and a Master of Business Administration degree from Seton Hall University. Mr. Cueto is also a Certified Public Accountant licensed in the State of New Jersey. Annonce • Sep 27
Azenta, Inc. Announces Executive Vice President Changes, Effective October 16, 2023 Azenta, Inc. announced that Herman Cueto will join Azenta as Executive Vice President, effective October 16, 2023. Mr. Cueto, who comes from BD (Becton, Dickinson and Company), will succeed Azenta Executive Vice President Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Mr. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of CR Bard. Mr. Cueto, age 49, previously served as the Senior Vice President of Finance of Becton, Dickinson and Company (NYSE: BDX), since June 2021, and served in senior financial and operations roles at Becton, Dickinson and Company since December 2017 including as the Senior Vice President and Chief Financial Officer of Becton, Dickinson and Company’s Medical Segment from January 2021 to June 2021. Prior to that, Mr. Cueto was at C.R. Bard, Inc. for fourteen years, most recently as Vice President and Group CFO. Mr. Cueto earned a Bachelor of Science and Master’s degrees from Fairleigh Dickinson University and a Master of Business Administration degree from Seton Hall University. Mr. Cueto is also a Certified Public Accountant licensed in the State of New Jersey. Annonce • Sep 17
Politan Capital Management Engages in Discussions with Azenta On September 14, 2023, Politan Capital Management LP announced that it has engaged and intends to continue to engage in discussions with certain members of Azenta, Inc.’s board of directors and management team regarding the Company’s business, operations, financial condition, strategic plans, governance, as well as other matters related to the Company, and intends to and may also engage with stockholders, industry analysts and other interested parties with respect to the foregoing. New Risk • Aug 17
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €466k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Significant insider selling over the past 3 months (€466k sold). Recent Insider Transactions • Aug 16
Insider recently sold €369k worth of stock On the 10th of August, Robin Vacha sold around 7k shares on-market at roughly €49.93 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €283k more than they sold in the last 12 months. Reported Earnings • Aug 09
Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.094 loss in 3Q 2022) Third quarter 2023 results: US$0.039 loss per share (improved from US$0.094 loss in 3Q 2022). Revenue: US$165.9m (up 25% from 3Q 2022). Net loss: US$2.46m (loss narrowed 65% from 3Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 3% per year. Annonce • Aug 04
Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023 Azenta, Inc. announced that they will report Q3, 2023 results After-Market on Aug 08, 2023 Breakeven Date Change • May 14
Forecast breakeven date pushed back to 2025 The 5 analysts covering Azenta previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 45% per year to 2024. The company is expected to make a profit of US$6.35m in 2025. Average annual earnings growth of 100% is required to achieve expected profit on schedule. Reported Earnings • May 10
Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.024 loss in 2Q 2022) Second quarter 2023 results: US$0.029 loss per share (further deteriorated from US$0.024 loss in 2Q 2022). Revenue: US$148.4m (up 2.0% from 2Q 2022). Net loss: US$1.99m (loss widened 9.6% from 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Annonce • May 10
Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023 Azenta, Inc. provided earnings guidance for the third quarter of fiscal year 2023. For the period, the company expected revenue to be in the range of $150 to $168 million. GAAP diluted loss per share from continuing operations is expected to be in the range of $0.29 to $0.19. Annonce • May 04
Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023 Azenta, Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023 Reported Earnings • Feb 09
First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.038 profit in 1Q 2022) First quarter 2023 results: US$0.15 loss per share (down from US$0.038 profit in 1Q 2022). Revenue: US$178.4m (up 28% from 1Q 2022). Net loss: US$11.2m (down 493% from profit in 1Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Annonce • Feb 09
Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023 Azenta, Inc. provided earnings guidance for the second quarter of fiscal year 2023. For the period, the company expected revenue to be in the range of $156 to $171 million. GAAP diluted loss per share from continuing operations is expected to be in the range of $0.24 to $0.16. Annonce • Feb 07
Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023 Azenta, Inc. announced that they will report Q1, 2023 results After-Market on Feb 08, 2023 Annonce • Feb 04
Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd. Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd on February 3, 2023. CEO and co-founder, Neil Benn will continue to lead the business as part of the Consumables and Instruments business within the Life Sciences Products segment.Azenta, Inc. (NasdaqGS:AZTA) completed the acquisition of Ziath Ltd on February 3, 2023. Annonce • Feb 03
Azenta, Inc. Announces Election of Directors Azenta, Inc. announced that at its Annual Meeting of the stockholders held on January 31, 2023, approved the election of Tina S. Nova and Dorothy E. Puh y as Directors. Annonce • Dec 22
Azenta, Inc., Annual General Meeting, Jan 31, 2023 Azenta, Inc., Annual General Meeting, Jan 31, 2023, at 10:00 Eastern Standard Time. Agenda: To elect ten director nominees; to approve, by a non-binding advisory vote, the compensation of the company’s named executive officers as disclosed in this proxy statement; and to ratify pricewaterhousecoopers llp as the company’s independent registered accounting firm for the 2023 fiscal year. Reported Earnings • Nov 16
Full year 2022 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2021) Full year 2022 results: US$0.15 loss per share (improved from US$0.39 loss in FY 2021). Revenue: US$555.5m (up 8.1% from FY 2021). Net loss: US$11.3m (loss narrowed 61% from FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Recent Insider Transactions • Aug 23
Executive VP & COO recently bought €500k worth of stock On the 19th of August, Matthew McManus bought around 9k shares on-market at roughly €57.92 per share. This was the largest purchase by an insider in the last 3 months. This was Matthew's only on-market trade for the last 12 months. Reported Earnings • Aug 11
Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.53 profit in 3Q 2021) Third quarter 2022 results: US$0.094 loss per share (down from US$0.53 profit in 3Q 2021). Revenue: US$132.7m (down 58% from 3Q 2021). Net loss: US$7.02m (down 118% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Reported Earnings • May 11
Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.32 profit in 2Q 2021) Second quarter 2022 results: US$0.024 loss per share (down from US$0.32 profit in 2Q 2021). Revenue: US$145.5m (down 49% from 2Q 2021). Net loss: US$1.82m (down 108% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Buying Opportunity • May 07
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 6.9%. The fair value is estimated to be €87.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Feb 09
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2022 results: EPS: US$0.038 (down from US$0.36 in 1Q 2021). Revenue: US$139.7m (down 44% from 1Q 2021). Net income: US$2.86m (down 89% from 1Q 2021). Profit margin: 2.0% (down from 11% in 1Q 2021). Revenue exceeded analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 15%, compared to a 16% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Breakeven Date Change • Dec 03
Forecast breakeven date pushed back to 2023 The 5 analysts covering Azenta previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 81% to 2022. The company is expected to make a profit of US$59.6m in 2023. Average annual earnings growth of 90% is required to achieve expected profit on schedule. Upcoming Dividend • Nov 25
Upcoming dividend of US$0.10 per share Eligible shareholders must have bought the stock before 02 December 2021. Payment date: 23 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.7%). Recent Insider Transactions • Nov 16
Independent Director recently sold €282k worth of stock On the 12th of November, Michael Rosenblatt sold around 3k shares on-market at roughly €99.69 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.8m more than they bought in the last 12 months. Reported Earnings • Nov 11
Full year 2021 earnings released: US$0.39 loss per share (vs US$0.88 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: US$513.7m (down 43% from FY 2020). Net loss: US$28.9m (down 144% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 61% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 7 highly experienced directors. Independent Director Erica McLaughlin was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 7 highly experienced directors. Independent Director Erica McLaughlin was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • Sep 30
Brooks Automation, Inc. Introduces Azenta Life Sciences to Advance Innovative Sample Solutions Brooks Automation, Inc. announced Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta"). Azenta will bring together company's existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions. The life sciences industry will benefit from the Azenta portfolio and vision with the integration of industry-leading capabilities within automated ultra-cold sample storage and sample repository solutions, sample sourcing and genomic services, data management and informatics, and consumables and instruments. Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment improved over the past week After last week's 15% share price gain to €89.50, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 32x in the Semiconductor industry in Germany. Total returns to shareholders of 217% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €56.07 per share.